IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4248
Positioning
Market Dominance
Manufacturing
Chemicals
$9M
Ofer Haviv
Evogene Ltd. focuses on product discovery and development in multiple life-science based industries, including human health and agriculture. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$EVGN Evogene Ltd. | 34 | 39 | 2 | 18 | - | - | -83.0% | -181.2% | 68.5% | -261.0% | -212.1% | 50.9% | 0.0% | - | $9M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Evogene Ltd. (EVGN) receives a "Avoid" rating with a composite score of 33.6/100. It ranks #4248 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Direct cash return
Ofer Haviv
Chief Executive Officer
Labor Force
140
39
63
43
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for EVGN
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Average quality profile
Average volatility — neutral timing signal
Conservative, efficient capex — capital discipline signals management quality
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for EVGN.
View All RatingsImproving capital utilization rates confirmed
High margin volatility — erratic forensic earnings quality
ROE proxy -83.0% (sector -2.5%)
GM 68% vs sector 43%, OM -261% vs sector 1%
Capital turnover N/A, R&D intensity 195.6%
Rev growth 51%, 8yr history
Interest coverage -6.6x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags Evogene Ltd. with an Avoid rating, assigning a composite score of 33.6/100 and 1 out of 5 stars. Ranked #4248 of 7,333 stocks, EVGN falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
EVGN's quality score of 39/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -83.0% (sector avg: -2.5%), gross margins of 68.5% (sector avg: 42.5%), net margins of -212.1% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
EVGN registers a value score of just 2/100, suggesting the stock trades at a significant premium to its fundamental metrics. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
EVGN shows a solid investment score of 63/100, reflecting measured but productive capital allocation. Key growth metrics include revenue growth of 50.9% vs. a sector average of 5.9% and a return on assets of -181.2% (sector: -0.1%). This suggests the company is investing at an appropriate level to sustain growth without overextending its balance sheet.
Evogene Ltd. is experiencing notably weak momentum with a score of just 18/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 50.9% year-over-year, while a beta of 0.63 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
EVGN's stability score of 43/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.63. Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 47/100 for EVGN suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include micro-cap liquidity risk. With a $9M market cap (micro-cap), Evogene Ltd. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
Evogene Ltd. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4248 of 7,333 overall (42nd percentile). Key comparisons include ROE of -83.0% trailing the -2.5% sector median and operating margins of -261.0% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While EVGN currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (2) would have the largest impact on the composite score.
ROE 3245% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 61% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 20329% BELOW SECTOR MEDIAN
AUDIT DATA AS OF DEC 31, 2024 (Q3 FY2024)
We rate Evogene Ltd. (EVGN) as Avoid with a composite score of 33.6/100 at a current price of $0.83. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in investment (63th percentile) and stability (43th percentile), which together account for the majority of the composite score. Offsetting weakness in value (2th percentile) and momentum (18th percentile) tempers our overall conviction. We assign a No Moat rating (24/100), Medium uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; sustainability of the current growth rate; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Evogene Ltd. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 33.6/100 places it at rank #4248 in our full 7,333-stock universe. At $9M in market capitalization, Evogene Ltd. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 51%, though momentum at the 18th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 68% (+26.0pp vs sector) narrow to operating margins of -261% (-262.3pp vs sector) and net margins of -212.1%, yielding a gross-to-net conversion rate of -310%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $0.83, Evogene Ltd. is trading at a premium to fundamental value. Our value factor score of 2/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/S of 0.2x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 68% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Revenue growth of 51% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
The Avoid rating (composite 33.6/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Thin net margins of -212.1% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Weak momentum (18th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
We assign a Medium uncertainty rating to Evogene Ltd.. The stock presents a balanced risk profile: current negative profitability (net margin -212.1%) and low beta of 0.63 — while defensive, this may indicate limited upside participation in bull markets. While not risk-free, the core business fundamentals are adequate to withstand moderate economic stress, and the range of potential outcomes around our fair value estimate is manageable.
Specific risk factors that inform our assessment include: current negative profitability (net margin -212.1%); low beta of 0.63 — while defensive, this may indicate limited upside participation in bull markets. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 43th percentile and quality factor at the 39th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 68% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate Evogene Ltd.'s capital allocation as Poor. Key concerns include low returns on equity (-83.0%), negative profitability, weak asset returns (ROA -181.2%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Evogene Ltd. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Evogene Ltd. receives a Avoid rating with a composite score of 33.6/100 (rank #4248 of 7,333). Our quantitative framework assigns a No Moat (24/100, trend: stable), Medium uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 33/100.
Our analysis does not support a constructive view on Evogene Ltd. at this time. The combination of limited competitive advantages, medium uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Evogene Ltd. a meaningful economic moat, scoring 24/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, growth durability, reached only 10/20.
The strongest moat sources are growth durability (10/20) and margin superiority (7.2/20). Rev growth 51%, 8yr history. GM 68% vs sector 43%, OM -261% vs sector 1%. These pillars form the core of Evogene Ltd.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (0/20) and financial resilience (0/20). ROE proxy -83.0% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Evogene Ltd.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 68% providing a solid profitability foundation, robust top-line growth of 51% expanding the revenue base. The margin cascade from 68% gross to -261% operating to -212.1% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 39th percentile.
The margin profile shows gross margins of 68%, operating margins of -261%, net margins of -212.1%. Return metrics include ROE of -83.0% and ROA of -181.2%. Relative to the Manufacturing sector, gross margins are 26.0 percentage points above the sector median of 43%, and ROE of -83.0% compares to a sector median of -2.5%.
The balance sheet reflects revenue growth of 51%. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
Evogene Ltd . (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the fourth quarter and full year 2025, on Thursday, March 5, 2026.
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries today announced a collaboration with the pioneering research group of Dr. Mark Adams, a leading cancer genomics expert in the School of Biomedical Sciences and Faculty of Health at the Queensland University of Technology (QUT), Australia. This partnership aims to accelerate the discovery and optimization
Upgrades For Invitation Homes Inc (NYSE:INVH), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the second quarter, Invitation Homes had an EPS of $0.44, compared to year-ago quarter EPS of $0.42. The stock has a 52-week-high of $36.53 and a 52-week-low of $28.52. At the end of the last trading period, Invitation Homes closed at $31.69. For Xylem Inc (NYSE:XYL), Melius Research upgraded the previous rating of Hold to Buy. In the second quarter, Xylem showed an EPS of $0.98, compared to $0.66 from the year-ago quarter. The current stock performance of Xylem shows a 52-week-high of $118.58 and a 52-week-low of $84.16. Moreover, at the end of the last trading period, the closing price was at $91.03. According to DA Davidson, the prior rating for Clorox Co (NYSE:CLX) was changed from Neutral to Buy. In the fourth quarter, Clorox showed an EPS of $1.67, compared to $0.93 from the year-ago quarter. At the moment, the stock has a 52-week-high of $178.21 and a 52-week-low of $124.59. Clorox closed at $131.06 at the end of the last trading period. BTIG upgraded the previous rating for LGI Homes Inc (NASDAQ:LGIH) from Sell to Neutral. For the second quarter, LGI Homes had an EPS of $2.25, compared to year-ago quarter EPS of $5.20. The stock has a 52-week-high of $141.91 and a 52-week-low of $74.61. At the end of the last trading period, LGI Homes closed at $99.49. Morgan Stanley upgraded the previous rating for United States Steel Corp (NYSE:X) from Equal-Weight to Overweight. In the second quarter, United States Steel showed an EPS of $1.92, compared to $3.86 from the year-ago quarter. The current stock performance of United States Steel shows a 52-week-high of $32.68 and a 52-week-low of $18.02. Moreover, at the end of the last trading period, the closing price was at $32.48. According to Susquehanna, the prior rating for FedEx Corp (NYSE:FDX) was changed from Neutral to Positive. In the first quarter, FedEx showed an EPS of $4.55, compared to $3.44 from the year-ago quarter. The stock has a 52-week-high of $270.95 and a 52-week-low of $147.33. At the end of the last trading period, FedEx closed at $264.92. For Rivian Automotive Inc (NASDAQ:RIVN), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. Rivian Automotive earned $1.08 in the second quarter, compared to $1.62 in the year-ago quarter. The current stock performance of Rivian Automotive shows a 52-week-high of $37.38 and a 52-week-low of $11.68. Moreover, at the end of the last trading period, the closing price was at $24.28. According to Piper Sandler, the prior rating for Zscaler Inc (NASDAQ:ZS) was changed from Neutral to Overweight. Zscaler earned $0.64 in the fourth quarter, compared to $0.25 in the year-ago quarter. The stock has a 52-week-high of $185.90 and a 52-week-low of $84.93. At the end of the last trading period, Zscaler closed at $155.59. For Datadog Inc (NASDAQ:DDOG), Piper Sandler upgraded the previous rating of Neutral to Overweight. Datadog earned $0.36 in the second quarter, compared to $0.24 in the year-ago quarter. The stock has a 52-week-high of $118.02 and a 52-week-low of $61.34. At the end of the last trading period, Datadog closed at $91.09. According to Piper Sandler, the prior rating for Macerich Co (NYSE:MAC) was changed from Underweight to Neutral. For the second quarter, Macerich had an EPS of $0.40, compared to year-ago quarter EPS of $0.46. The stock has a 52-week-high of $14.51 and a 52-week-low of $7.73. At the end of the last trading period, Macerich closed at $10.91. According to Jefferies, the prior rating for Insulet Corp (NASDAQ:PODD) was changed from Hold to Buy. Insulet earned $0.38 in the second quarter, compared to $0.06 in the year-ago quarter. At the moment, the stock has a 52-week-high of $335.91 and a 52-week-low of $152.43. Insulet closed at $159.49 at the end of the last trading period. For Mr. Cooper Group Inc (NASDAQ:COOP), Keefe, Bruyette & Woods upgraded the previous rating of Market Perform to Outperform. For the second quarter, Mr. Cooper Gr had an EPS of $1.66, compared to year-ago quarter EPS of $0.17. The current stock performance of Mr. Cooper Gr shows a 52-week-high of $60.68 and a 52-week-low of $37.54. Moreover, at the end of the last trading period, the closing price was at $53.56. According to Keefe, Bruyette & Woods, the prior rating for PennyMac Financial Services Inc (NYSE:PFSI) was changed from Market Perform to Outperform. PennyMac Financial Servs earned $1.11 in the second quarter, compared to $2.28 in the year-ago quarter. The current stock performance ...Full story available on Benzinga.com
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -94.12% and 4.23%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 21.05% and 97.18%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?